Efficacy and safety of nilotinib in patients with chronic graft versus host disease (GVHD) who did not respond to imatinib mesylate
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 30 Aug 2017
At a glance
- Drugs Nilotinib (Primary) ; Imatinib
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- Acronyms Double-ITK-GVHc
- 24 Aug 2017 Planned End Date changed from 1 Mar 2023 to 1 Mar 2018.
- 24 Aug 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Mar 2018.
- 01 Sep 2016 Status changed to active, no longer recruiting.